AstraZeneca Aims To Speed Drugs To China Market with New JV
As the Chinese government looks to promote 'made in China' innovation, AstraZeneca has established a joint venture called Dizal Pharmaceuticals in tandem with a well-financed and influential local fund.
You may also be interested in...
AstraZeneca agreed two new deals with Chinese tech groups Alibaba and Tencent as it tries to expand business in modernizing China, now the UK drug maker's second-largest market after the US.
Janssen and French biotech Dynacure take licenses to antisense candidates arising from Ionis’ Generation 2.5 technology. Merck and Cue sign autoimmune partnership, while Bayer and PeptiDream ink discovery pact.
AstraZeneca, which unlike many of its multinational peers continues to show strong growth in China, is building on this with a large investment aimed at building capacity for the development and manufacture of pharmaceuticals in the region.